logo-loader

Dalrada Corporation - Good to be green

Last updated: 09:17 01 Jul 2021 EDT, First published: 09:16 01 Jul 2021 EDT

Dalrada is a global company that operates under the tenet of creating impactful innovations that matter for the world. The company holds a portfolio of subsidiaries comprising early-stage high growth businesses and covering three verticals: Healthcare, Engineering, and Information Technology Solutions. For its last reported financial quarter (March 2021) the company achieved revenue growth of 352% year-on-year (YoY) or 50% growth quarter-on-quarter. We argue that Dalrada is at or close to inflexion points in growth in multiple business units, and we examine these growth prospects in this report. We pay particular attention to four business units:

Likido Energy is an engineering company with products based around innovative heat pump renewable clean technology, which offer transformational energy savings for a range of industrial, commercial and domestic applications. Likido is targeting new customer orders during 2021 that would raise the business's revenue generation by an order of magnitude, driven by sustainability goals for multiple customer industries.

Prakat Solutions is Dalrada’s Information Systems business, providing enterprise-level software services for a global customer base. Prakat has benefited from strong demand for its services in support of business continuity, technology as a necessity and work-from-home solutions, and we are forecasting continued revenue momentum for this business.

Dalrada Healthcare has developed a single-use test kit for the detection of cervical cancer, which offers life-saving screening capability applicable in localities with limited healthcare infrastructure. The company is pursuing national scale orders in India and other countries.

Regenerative therapies using alternative options such as stem cells and rehabilitation services, combined with data-driven genomic products for better outcomes. This division has ambitious expansion plans based on its established expertise within these disciplines.

 

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities,...

FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:

This document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.

Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO

FOR OUR FULL DISCLAIMER CLICK HERE

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

9 hours, 53 minutes ago